Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Itacitinib in Combination With Tocilizumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease

NCT04070781 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT04070781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04070781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Itacitinib in Combination With Tocilizumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease
Lead sponsor
Columbia University
Phase
Phase 1
Overall status
Terminated
Start date
January 20, 2020
Completion date
December 13, 2021
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

graft vs host disease, steroid refractory gvhd